|1.||Singh, Inderjit: 13 articles (09/2013 - 11/2002)|
|2.||Dimitroulakos, Jim: 11 articles (01/2014 - 07/2002)|
|3.||Pan, Tzu-Ming: 11 articles (12/2013 - 01/2003)|
|4.||Singh, Avtar K: 10 articles (09/2013 - 11/2002)|
|5.||Paintlia, Manjeet K: 7 articles (09/2013 - 10/2004)|
|6.||Paintlia, Ajaib S: 7 articles (09/2013 - 10/2004)|
|7.||Jakóbisiak, Marek: 7 articles (01/2008 - 02/2002)|
|8.||Dimitroulakos, J: 6 articles (08/2010 - 12/2000)|
|9.||Gotto, A M: 6 articles (12/2001 - 02/2000)|
|10.||Weis, S: 6 articles (12/2001 - 02/2000)|
01/01/1988 - "Lovastatin is highly effective in the treatment of primary hypercholesterolemia and represents an important therapeutic advance. "
11/28/1986 - "In this study, lovastatin was a well tolerated and effective agent for the treatment of nonfamilial hypercholesterolemia."
04/01/2002 - "Our results suggest a mechanism by which hypercholesterolemia may increase risk for AD and indicate that lovastatin reduces Abeta formation and may thereby be effective in delaying the onset and/or slowing the progression of AD."
04/05/1995 - "The increase in HDL-C associated with lovastatin lowered cost-effectiveness ratios by approximately 40%, such that the treatment of hypercholesterolemia was relatively cost-effective for men (as low as $20,882 per year of life saved at age 50 years) and women ($36,627 per year of life saved at age 60 years) with additional risk factors. "
01/01/2002 - "Because lovastatin is efficiently extracted by the liver and because its administration in divided doses is associated with increased efficacy, an extended-release (ER) formulation may have the potential for a dose-sparing advantage relative to the immediate-release (IR) formulation in the treatment of hypercholesterolemia. "
|2.||Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
05/01/1989 - "In this study, lovastatin was a well tolerated and effective agent for the treatment of non familial and heterozygous familial hypercholesterolemia."
11/01/1987 - "Lovastatin was well tolerated and effective in the treatment of familial hypercholesterolemia."
09/01/2005 - "Lovastatin offers an efficacious and well-tolerated treatment option for improving lipid profiles in adolescent girls with familial hypercholesterolemia."
09/01/1986 - "Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia."
09/01/2005 - "The present study was designed to evaluate the lipid-altering efficacy, safety, and tolerability of lovastatin treatment in adolescent girls with heterozygous familial hypercholesterolemia. "
|3.||Nephrotic Syndrome (Syndrome, Nephrotic)
01/01/1994 - "Lovastatin ameliorates depressed intraglomerular proteolytic activities in experimental nephrotic syndrome."
01/01/1994 - "Remission of nephrotic syndrome on lovastatin treatment."
05/01/1994 - "Eight patients with biopsy-proven primary nephrotic syndrome were included in an open, prospective, two-year study of lovastatin. "
01/01/1994 - "The aim of the present study was to investigate whether lovastatin treatment, which prevents progressive glomerulosclerosis in experimental nephrotic syndrome, would also have an effect on glomerular proteinase activities. "
07/01/1995 - "We administered lovastatin (40 to 80 mg/day) to 20 adult patients with unremitting nephrotic syndrome for 8 weeks to assess its effect on plasma Lp(a) and other plasma lipid concentrations. "
02/20/2015 - "Lovastatin significantly enhanced the efficacy of PRRA-TRAIL by promoting the in vivo tumor suppression, and the in vitro cell killing and apoptosis induction, via integration of multiple molecular mechanisms. "
11/01/2013 - "The aim of this study was to determine the type of cell death induced by lovastatin on human colon tumor cells by using the neutral comet assay and to evaluate the utility of this method for detection of apoptosis. "
01/01/2007 - "We investigated the molecular mechanism of Lovastatin anti-tumor function through the study of its effect on membrane ion flow, gap junctional intercellular communication (GJIC), and the pathways of related signals in MCF-7 mammary cancer cells. "
10/01/2004 - "In a corollary in vitro study, flow cytometric analyses of lovastatin-treated mammary cancer cells additionally showed cell cycle arrest at G1 phase and decreases in S and G2/M phases. "
09/15/2004 - "Our study suggests that lovastatin, alone or in combination with a MEK1 inhibitor, may represent a new and immediately available therapeutic approach to combat tumors with activated ERK1/2, such as AML."
11/01/2012 - "In vivo studies using the Triton-induced hyperlipidemia model in Wistar rats revealed considerable reduction in lipid levels compared to pure lovastatin. "
01/01/2015 - "Golden hamsters were fed a high-fat diet (HFD) for 6 weeks to induce hyperlipidemia, followed by oral treatment with 50 and 100 mg/kg/day of BBR or 10 and 30 mg/kg/day of lovastatin for 10 days, respectively. "
01/01/2013 - "Parameters were altered during hyperlipidemia and reverted back to near normal values after Et-CAF treatment or standard drug lovastatin. "
10/01/2011 - "Similar effects from lovastatin on lipidemia were observed except the Ber effect on CPT I A gene expression. "
10/01/2011 - "Male SD rats were randomly divided into 5 groups according to the blood lipid values: normal group, hyperlipidemia group, 300 mg x kg(-1) x d(-1) Ber-treated group, 60 mg x kg(-1) x d(-1) Ber-treated group, and 7.2 mg x kg(-1) x d(-1) lovastatin-treated group. "
|8.||Niacin (Nicotinic Acid)
|1.||Heart Transplantation (Grafting, Heart)
|2.||Diet Therapy (Therapy, Diet)
|3.||Combination Drug Therapy (Combination Chemotherapy)
|4.||Continuous Ambulatory Peritoneal Dialysis (CAPD)
|5.||Cardiopulmonary Resuscitation (CPR)